GO:1905907 negative regulation of amyloid fibril formation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905907 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of amyloid fibril formation.
• Amyloid fibril formation is a nucleation-dependent process, and its negative regulation can occur at primary nucleation, secondary nucleation, or elongation steps.
• Key negative regulators include chaperones, proteases, autophagy components, and small molecules that stabilize native protein conformations or clear aggregates.
• Dysregulation of this process is linked to Alzheimer's disease, type 2 diabetes, and other amyloidoses, making it a therapeutic target.
• Plasma phospho-tau217 is a validated biomarker for Alzheimer's disease diagnosis, reflecting amyloid-related pathology.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of genes that negatively regulate amyloid fibril formation.
Description
Amyloid fibrils are ordered protein aggregates that arise from the misfolding of normally soluble proteins. The process of amyloid fibril formation is implicated in a wide range of human disorders, including Alzheimer's disease, Parkinson's disease, and type 2 diabetes. The Gene Ontology term GO:1905907, negative regulation of amyloid fibril formation, captures any process that stops, prevents, or reduces the frequency, rate, or extent of this aggregation. Understanding this regulatory process is critical because enhancing negative regulation may offer therapeutic strategies to combat amyloid-related pathologies. Recent advances in biomarker discovery, such as plasma phospho-tau217 for Alzheimer's disease, highlight the clinical importance of amyloid-related processes. Moreover, the interplay between amyloid formation and cellular pathways like autophagy and neuroinflammation underscores the complexity of these regulatory mechanisms.
negative regulation of amyloid fibril formation At A Glance
| GO ID | GO:1905907 |
|---|---|
| GO term | negative regulation of amyloid fibril formation |
| Ontology | biological_process |
| Synonym | inhibition of amyloid fibril formation; down-regulation of amyloid fibril assembly; negative regulation of amyloid structure formation |
| Major function | Prevents or reduces the formation of amyloid fibrils, which are pathological protein aggregates. |
| Related processes | Protein folding, proteostasis, autophagy, and cellular stress responses. |
| Disease relevance | Alzheimer's disease, Parkinson's disease, type 2 diabetes, and other amyloidoses. |
| Experimental approaches | CRISPR knockout/knock-in, biochemical aggregation assays, imaging, and omics. |
What Is GO:1905907?
GO:1905907 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of amyloid fibril formation. This biological process encompasses molecular events that inhibit the assembly of proteins into amyloid fibrils, which are characterized by a cross-beta sheet structure. Negative regulation can occur through diverse mechanisms, including chaperone-mediated prevention of misfolding, proteolytic degradation of aggregation-prone species, and small-molecule interference with nucleation or elongation.
Why Is negative regulation of amyloid fibril formation Important in Cell Biology?
Negative regulation of amyloid fibril formation is crucial for maintaining proteostasis and preventing the accumulation of toxic protein aggregates. Dysregulation of this process is a hallmark of numerous neurodegenerative and systemic amyloid diseases. Elucidating the molecular players and mechanisms that negatively regulate amyloid formation can reveal therapeutic targets and biomarkers, such as plasma phospho-tau217 for Alzheimer's disease. Furthermore, understanding how cells naturally counteract amyloidogenesis may inform the development of interventions that boost these protective pathways.
• Prevents toxic protein aggregation linked to neurodegeneration.
• Maintains proteostasis by balancing protein folding and clearance.
• Involved in Alzheimer's disease pathogenesis and cognitive decline.
• Provides biomarkers like plasma phospho-tau217 for diagnosis.
• Offers targets for therapeutic intervention in amyloidoses.
• Modulated by autophagy and neuroinflammatory pathways.
• Affects functional amyloids with roles in stress granules.
• Influenced by lipid environments and cholesterol derivatives.
• Regulated by hormones such as parathyroid hormone.
• Can be studied using CRISPR-based gene editing models.
What Happens During negative regulation of amyloid fibril formation?
Inhibition of Primary Nucleation
In simple terms: Stopping the very first step where protein molecules start to clump together.
Primary nucleation is the initial step in amyloid fibril formation, where monomeric proteins assemble into oligomeric nuclei. Negative regulation at this stage can involve molecular chaperones that bind to misfolded monomers and prevent their aggregation. For example, activation of PPARA-mediated autophagy reduces amyloid pathology by enhancing clearance of aggregation-prone species. Additionally, charged cholesterol derivatives can modulate Aβ40 amyloid formation, suggesting that lipid environments influence primary nucleation.
Inhibition of Secondary Nucleation
In simple terms: Preventing existing fibrils from catalyzing the formation of new fibrils.
Secondary nucleation occurs when existing fibrils catalyze the formation of new nuclei, amplifying aggregation. Negative regulators can interfere with this process by stabilizing fibril ends or altering fibril surface properties. A study on parathyroid hormone revealed a competition between secondary and primary nucleation, indicating that modulators can shift the balance away from fibril amplification. This step is a key target for therapeutic intervention because secondary nucleation is a major source of toxic oligomers.
Enhancement of Protein Clearance
In simple terms: Helping cells remove the proteins that could form amyloid.
Cellular clearance mechanisms, such as autophagy and proteasomal degradation, remove misfolded proteins and aggregates. Activation of PPARA-mediated autophagy has been shown to reduce Alzheimer disease-like pathology and cognitive decline in a murine model, demonstrating that enhancing clearance negatively regulates amyloid fibril formation. Similarly, astrocytic Mettl14 depletion attenuates astrogliosis and neuroinflammation, indirectly supporting clearance pathways.
Modulation by Endogenous Factors
In simple terms: Natural molecules in the body that can slow down amyloid formation.
Endogenous molecules can act as negative regulators. Amyloid beta peptide itself acts as an endogenous negative allosteric modulator of the leptin receptor, illustrating a feedback mechanism that may influence amyloidogenesis. Additionally, functional amyloid protein FXR1 is recruited into neuronal stress granules, suggesting that some amyloid-like assemblies are tightly regulated and may not be pathological. These examples highlight the complexity of endogenous regulation.
Key Genes Involved in GO:1905907 negative regulation of amyloid fibril formation
The following genes and proteins have been implicated in the negative regulation of amyloid fibril formation, based on experimental evidence from the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PPARA | Activates autophagy, reducing amyloid pathology | Target for Alzheimer's disease therapy |
| MAPT | Encodes tau; phospho-tau217 is a biomarker | Diagnosis of Alzheimer's disease |
| PTH | Parathyroid hormone; its fibril formation is regulated by nucleation | Model for amyloid fibril kinetics |
| LEPR | Leptin receptor; modulated by amyloid beta | Link between amyloid and metabolic signaling |
| FXR1 | Functional amyloid recruited to stress granules | Neuronal stress response |
| METTL14 | RNA methyltransferase; astrocytic depletion reduces neuroinflammation | Modulates amyloid-related pathology |
| APP | Amyloid precursor protein; source of Aβ | Central to Alzheimer's disease |
| PSEN1 | Presenilin 1; component of γ-secretase | Familial Alzheimer's disease |
| DUSP1 | MAPK phosphatase; involved in astrogliosis | Neuroinflammation pathway |
| MAPK1 | Mitogen-activated protein kinase | Signaling in neuroinflammation |
| BECN1 | Autophagy regulator | Enhances clearance of aggregates |
| SQSTM1 | Autophagy receptor | Targets aggregates for degradation |
| HSPA1A | Chaperone | Prevents protein misfolding |
| HSPB1 | Small heat shock protein | Inhibits amyloid fibril formation |
| CTSB | Cathepsin B; protease | Degrades amyloidogenic peptides |
| LAMP1 | Lysosomal marker | Autophagy-lysosome pathway |
| TFEB | Transcription factor for autophagy | Master regulator of clearance |
How Is negative regulation of amyloid fibril formation Regulated?
The negative regulation of amyloid fibril formation is controlled by multiple cellular pathways. Autophagy, a major clearance mechanism, is regulated by PPARA and TFEB, and its activation reduces amyloid pathology. Neuroinflammatory pathways involving METTL14, DUSP1, and MAPK signaling can modulate the cellular environment and influence amyloid deposition. Additionally, endogenous factors like amyloid beta can allosterically modulate receptors such as LEPR, potentially affecting downstream signaling. The balance between primary and secondary nucleation is also subject to regulation by the physicochemical properties of the protein and its environment.
negative regulation of amyloid fibril formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PPARA | Alzheimer's disease | Knockout and overexpression in APP/PS1 mice |
| MAPT | Alzheimer's disease, tauopathies | Point mutation knock-in of P301S |
| METTL14 | Alzheimer's disease, neuroinflammation | Astrocyte-specific knockout |
| APP | Alzheimer's disease | Knock-in of Swedish mutation |
| FXR1 | Stress granule biology | Tagged knock-in for imaging |
Alzheimer's Disease
Alzheimer's disease is characterized by amyloid-beta plaques and tau tangles. Negative regulation of amyloid fibril formation is impaired in Alzheimer's disease, leading to accumulation of Aβ fibrils. Activation of PPARA-mediated autophagy reduces amyloid pathology and cognitive decline in murine models. Plasma phospho-tau217 has emerged as a highly accurate biomarker for Alzheimer's disease diagnosis, reflecting amyloid-related neurodegeneration. Astrocytic METTL14 depletion attenuates astrogliosis and neuroinflammation, improving cognitive function in APP/PS1 mice.
Type 2 Diabetes and Other Amyloidoses
Amyloid fibril formation is also implicated in type 2 diabetes (islet amyloid polypeptide) and other systemic amyloidoses. The general principles of negative regulation, such as chaperone activity and clearance, apply across these diseases. The amyloid state of proteins can be either beneficial or detrimental, as seen with functional amyloids like FXR1 in stress granules. Understanding negative regulation in these contexts may lead to broad-spectrum therapeutic strategies.
Neuroinflammation and Stress Responses
Neuroinflammation exacerbates amyloid pathology. Astrocytic METTL14 depletion reduces astrogliosis via the DUSP1/MAPK pathway, attenuating neuroinflammation in Alzheimer's disease models. This suggests that negative regulation of amyloid fibril formation can be influenced by inflammatory signaling. Additionally, functional amyloid protein FXR1 is recruited into neuronal stress granules, indicating a role for amyloid-like assembly in stress responses.
From negative regulation of amyloid fibril formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate amyloid fibril formation? | CRISPR knockout in cell culture, followed by aggregation assays |
| Does a specific mutation affect the anti-amyloid function? | Point mutation knock-in using CRISPR |
| Can overexpression of a chaperone reduce amyloid burden? | Transgenic overexpression in mouse models |
| How does a gene product localize during amyloid formation? | Tagged knock-in with fluorescent protein |
| What is the effect of gene dosage on amyloid pathology? | Heterozygous knockout or conditional knock-in |
| Can CRISPR activation (CRISPRa) upregulate protective genes? | Overexpression via CRISPRa in cell models |
How to Study the negative regulation of amyloid fibril formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thioflavin T fluorescence | Amyloid fibril formation kinetics | In vitro aggregation assays |
| Fluorescence microscopy | Cellular localization of aggregates | Stress granule recruitment |
| RNA-seq | Transcriptional changes | Neuroinflammation pathways |
| Proteomics | Protein composition of aggregates | Identification of amyloid components |
| CRISPR knockout screening | Genes that regulate amyloid formation | Discovery of negative regulators |
| Western blot | Protein levels and aggregation state | Validation of clearance |
| ELISA | Quantification of specific peptides (e.g., Aβ) | Biomarker measurement |
| Autophagy flux assay | Autophagic degradation activity | PPARA-mediated clearance |
Biochemical Aggregation Assays
Thioflavin T fluorescence and sedimentation assays are standard for monitoring amyloid fibril formation in vitro. These methods can be used to test the effect of purified proteins or small molecules on nucleation and elongation. Kinetic analysis can distinguish effects on primary versus secondary nucleation.
Cell-Based Imaging
Fluorescence microscopy with amyloid-specific dyes (e.g., thioflavin S, Congo red) or tagged proteins allows visualization of amyloid aggregates in cells. Live-cell imaging can track the recruitment of proteins like FXR1 into stress granules. Co-localization with autophagy markers (e.g., LC3) can assess clearance.
Omics Approaches
Transcriptomics and proteomics can identify genes and proteins that change during amyloid formation or in response to negative regulators. For example, RNA-seq of APP/PS1 mice with METTL14 depletion revealed changes in neuroinflammatory pathways. Proteomic analysis of amyloid plaques can uncover novel regulators.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can systematically identify negative regulators of amyloid fibril formation. Cells expressing a fluorescent amyloid reporter can be sorted to enrich for modulators. This approach has been used to discover autophagy-related genes.
How CRISPR Can Be Used to Study GO:1905907 negative regulation of amyloid fibril formation
Knockout
CRISPR knockout is used to delete candidate genes and assess whether their loss increases amyloid fibril formation. For example, knocking out PPARA in cell or mouse models would test its role in autophagy-mediated clearance. Knockout of METTL14 in astrocytes demonstrated reduced neuroinflammation and improved cognition in APP/PS1 mice.
Point Mutation
Point mutations can mimic disease-associated variants or disrupt specific functional domains. For instance, introducing the P301S mutation in MAPT via CRISPR knock-in creates a tauopathy model. Such models help determine whether a mutation affects the negative regulation of amyloid formation.
Knock-in
Knock-in of reporter tags (e.g., GFP) allows real-time tracking of proteins involved in amyloid regulation. Tagged FXR1 knock-in mice can reveal its recruitment to stress granules. Knock-in of human APP mutations (e.g., Swedish) creates Alzheimer's disease models.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can boost levels of protective genes to test their capacity to reduce amyloid burden. Overexpression of PPARA or TFEB enhances autophagy and reduces amyloid pathology. This approach is valuable for validating therapeutic targets.
How EDITGENE Supports negative regulation of amyloid fibril formation Research
Researchers studying negative regulation of amyloid fibril formation-related genes often need to determine whether a candidate gene is causally involved in preventing or reducing amyloid aggregation. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation of these regulatory genes.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of amyloid fibril formation research.
Frequently Asked Questions About negative regulation of amyloid fibril formation
What is GO:1905907?
GO:1905907 is the Gene Ontology term for negative regulation of amyloid fibril formation, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of amyloid fibril formation.
What genes are involved in negative regulation of amyloid fibril formation?
Key genes include PPARA, MAPT, METTL14, APP, PSEN1, BECN1, and SQSTM1, among others.
How does autophagy regulate amyloid fibril formation?
Autophagy clears misfolded proteins and aggregates; activation of PPARA-mediated autophagy reduces amyloid pathology in Alzheimer's disease models.
What is the role of METTL14 in amyloid formation?
Astrocytic METTL14 depletion attenuates astrogliosis and neuroinflammation via the DUSP1/MAPK pathway, improving cognition in APP/PS1 mice.
Can CRISPR be used to study negative regulation of amyloid fibril formation?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models allow functional testing of candidate genes.
What biomarkers are used for amyloid-related diseases?
Plasma phospho-tau217 is a validated biomarker for Alzheimer's disease diagnosis, reflecting amyloid pathology.
How do chaperones negatively regulate amyloid formation?
Chaperones bind misfolded proteins and prevent their aggregation into fibrils, as reviewed in the context of the amyloid state.
What is the difference between primary and secondary nucleation?
Primary nucleation is the initial formation of nuclei from monomers, while secondary nucleation is the catalysis of new nuclei by existing fibrils; both can be negatively regulated.
Is amyloid fibril formation always harmful?
No, functional amyloids exist, such as FXR1 in stress granules, and can have beneficial roles.
What experimental models are available for studying amyloid regulation?
Models include CRISPR knockout/knock-in mice, cell culture aggregation assays, and omics approaches.
Conclusion
GO:1905907, negative regulation of amyloid fibril formation, is a critical biological process that counteracts the accumulation of toxic protein aggregates. Its dysregulation is central to Alzheimer's disease and other amyloidoses, and understanding its mechanisms offers promising therapeutic avenues. CRISPR-based models and advanced omics technologies are indispensable for dissecting the genes and pathways involved. EDITGENE provides the tools and expertise to accelerate this research.
References
- 1. Luo R et al.. 2020. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.. Autophagy 16(1):52-69 PMID: 30898012
- 2. Palmqvist S et al.. 2025. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform.. Nat Med 31(6):2036-2043 PMID: 40205199
- 3. Voigt B et al.. 2023. A Competition of Secondary and Primary Nucleation Controls Amyloid Fibril Formation of the Parathyroid Hormone.. Macromol Biosci 23(4):e2200525 PMID: 36811263
- 4. Cecon E et al.. 2021. Amyloid Beta Peptide Is an Endogenous Negative Allosteric Modulator of Leptin Receptor.. Neuroendocrinology 111(4):370-387 PMID: 32335558
- 5. Valina AA et al.. 2025. Functional amyloid protein FXR1 is recruited into neuronal stress granules.. Prion 19(1):1-16 PMID: 40411539
- 6. Teng Y et al.. 2026. Astrocytic Mettl14 depletion enhances cognitive function by attenuating astrogliosis via the DUSP1/MAPK pathway in APP/PS1 mice: targeting neuroinflammation in Alzheimer's disease.. Mol Psychiatry 31(1):318-331 PMID: 40914755
- 7. Elbassal EA et al.. 2016. Effects of Charged Cholesterol Derivatives on Aβ40 Amyloid Formation.. J Phys Chem B 120(1):59-68 PMID: 26652010
- 8. Hassan MN et al.. 2022. The amyloid state of proteins: A boon or bane?. Int J Biol Macromol 200:593-617 PMID: 35074333
